RBC Capital raises UnitedHealth stock price target to $400 on strong Q1

RBC Capital raised its price target on UnitedHealth to $400 from $361 and reiterated Outperform after the company’s first-quarter 2026 results showed a significant medical care ratio beat and better-than-expected OptumHealth margins. UnitedHealth also beat on Q1 adjusted EPS at $7.23 versus $6.59 expected and revenue at $111.7 billion versus $109.44 billion, while lifting 2026 EPS guidance to $18.25 from $17.75. The stock has rallied more than 10% in the past week to $346.01, though it still trades below InvestingPro’s fair value estimate of $395.

Analysis

UNH is moving from a distressed multiple toward a re-rating story, but the more important signal is that the earnings beat is coming from operating discipline rather than one-off financial engineering. That matters because managed care names usually only sustain multiple expansion when investors believe the medical-cost cycle is peaking and margin recovery can compound for several quarters; if that thesis holds, UNH can keep tightening the spread between its current multiple and the peer group over the next 2-3 earnings prints.

The second-order beneficiary is the broader large-cap managed care complex: if UNH can print a clean beat-and-raise cadence, capital will rotate back into sector leaders that had been treated as structurally ex-growth. The losers are smaller providers and outsourcing adjacencies that were implicitly relying on persistently loose reimbursement or elevated utilization assumptions; a better UNH margin profile usually means tighter negotiating leverage across the ecosystem.

The main risk is that this is a short-duration rally being driven by relief rather than conviction. If government/trend assumptions slip, the market will likely de-rate the 2027 earnings multiple quickly, because the current setup is highly dependent on continued quarterly proof rather than long-term narrative alone. In other words, the stock can work for months if guidance ratchets up, but the tape is vulnerable to a single quarter that shows care-cost normalization stalling or Optum momentum fading.

Consensus may be underestimating how much of the upside is already embedded after the recent jump: the easy part is the multiple recovery from depressed levels, while the hard part is sustaining it without a broader healthcare risk-on rotation. The contrarian angle is that if UNH keeps outperforming, the best expression may not be outright long UNH but long UNH versus lower-quality managed care peers that have weaker visibility and less operational leverage.

Key Decisions for Investors

• Own UNH on pullbacks for a 1-2 quarter trade: upside is driven by continued beat-and-raise revisions; risk is a quick de-rating if next guidance disappoints.
• Pair trade: long UNH / short a weaker-quality managed care peer basket over the next 3-6 months; thesis is that the market will reward visible margin recovery while punishing names with less earnings visibility.
• Sell near-dated UNH put spreads into strength if you want to express a moderated bullish view; the setup favors upside continuation, but realized volatility may compress after this rerating leg.
• If already long, trim 20-30% after sharp post-earnings momentum and re-add only on evidence of another quarter of margin durability; this reduces the risk of chasing a relief move that stalls.